

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	09/836,627	SCOTT ET AL.	
	Examiner	Art Unit	
	Humera N. Sheikh	1615	

All Participants:

(1) Humera N. Sheikh.

(2) Rosemary M. Miano.

Status of Application: Allowed

(3) _____.

(4) _____.

Date of Interview: 6 February 2006

Time: 4pm (EST)

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description: _____.

Part I.

Rejection(s) discussed:

none

Claims discussed:

none

Prior art documents discussed:

none

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

 2/6/06
 (Examiner/SPE Signature)

 (Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Examiner requested and received source/manufacture information from Applicant's representative regarding the following tradenames/trademarks: (1) Eudragit® S100; (2) Eudragit® L100; (3) Claversal® and (4) Salofalk®. These trademarks/tradenames are listed in the specification on page 2, lines 10-13. Applicant indicated that (1) Eudragit® S100/L100 are available from Roehm GmbH, Darmstadt, Germany (also see U.S. Patent No. 6,228,396) regarding source/manufacture of Eudragit® forms; (2) Claversal® is available from GlaxoSmithKline, Madrid, Spain; (3) Salofalk® - available by Dr. Falk Pharma, GmbH, Freiburg, Germany. Examiner requested and received approval from Applicant's representative to incorporate the trademark/tradename information through an Examiner's Amendment. A Notice of Allowability will soon be issued.